6-methoxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione | 1018339-99-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 萘并吡喃类
• 英文名称: 6-methoxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
• 英文别名: 6-methoxy-2,2-dimethyl-2H,5H,10H-benzo[g]chromene-5,10-dione；6-methoxy-2,2-dimethylbenzo[g]chromene-5,10-dione
• CAS: 1018339-99-5
• 化学式: C₁₆H₁₄O₄
• 分子量: 270.285
• InChiKey: QMGSLQUQZVBKNH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-甲基-2-丁烯醛 、 2-hydroxy-5-methoxynaphthalene-1,4-dione 在 溶剂黄146 、 β-丙氨酸 作用下， 以 苯 为溶剂， 反应 18.0h， 以76%的产率得到6-methoxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
  参考文献：
  名称：

  Indoleamine 2,3-Dioxygenase Is the Anticancer Target for a Novel Series of Potent Naphthoquinone-Based Inhibitors

  摘要：

  Indoleamine 2,3-dioxygenase (IDO) is emerging as an important new therapeutic target for the treatment of cancer, chronic viral infections, and other diseases characterized by pathological immune suppression. While small molecule inhibitors of IDO exist, there remains a dearth of high-potency compounds offering in vivo efficacy and clinical translational potential. In this study, we address this gap by defining a new class of naphthoquinone-based IDO inhibitors exemplified by the natural product menadione, which is shown in mouse tumor models to have similar antitumor activity to previously characterized IDO inhibitors. Genetic validation that IDO is the critical in vivo target is demonstrated using IDO-null mice. Elaboration of menadione to a pyranonaphthoquinone has yielded low nanomolar potency inhibitors, including new compounds which are the most potent reported to date (K-i = 61-70 nM). Synthetic accessibility of this class will facilitate preclinical chemical-genetic studies as well as further optimization of pharmacological parameters for clinical translation.

  DOI：

  10.1021/jm7014155

文献信息

• Palladium(II)-Catalyzed C–H Bond Activation/C–C Coupling/Intramolecular Tsuji–Trost Reaction Cascade: Facile Access to 2<i>H</i>-Pyranonaphthoquinones
  作者：Jinlei Bian、Xue Qian、Nan Wang、Tong Mu、Xiang Li、Haopeng Sun、Lianshan Zhang、Qidong You、Xiaojin Zhang

  DOI：10.1021/acs.orglett.5b01304

  日期：2015.7.17

  An efficient one-pot synthesis of 2H-pyranonaphthoquinone was achieved via a palladium-catalyzed C–H bond activation/C–C bond formation/intramolecular Tsuji–Trost reaction cascade. The unprecedented procedure exhibits excellent functional group tolerance, giving the target naphthoquinones in moderate to good isolated yields (40–88%) under mild reaction conditions. Scalable production of the product

  通过钯催化的CH键活化/ CC键形成/分子内Tsuji-Trost反应级联，可以有效地一锅合成2 H-吡喃并萘醌。前所未有的方法显示出优异的官能团耐受性，在温和的反应条件下，目标萘醌的分离产率中等至良好（40-88％）。产品的可扩展生产可使该反应成为合成2 H-吡喃并萘醌的一种选择方法。
• Indoleamine 2,3-Dioxygenase Is the Anticancer Target for a Novel Series of Potent Naphthoquinone-Based Inhibitors
  作者：Sanjeev Kumar、William P. Malachowski、James B. DuHadaway、Judith M. LaLonde、Patrick J. Carroll、Daniel Jaller、Richard Metz、George C. Prendergast、Alexander J. Muller

  DOI：10.1021/jm7014155

  日期：2008.3.1

  Indoleamine 2,3-dioxygenase (IDO) is emerging as an important new therapeutic target for the treatment of cancer, chronic viral infections, and other diseases characterized by pathological immune suppression. While small molecule inhibitors of IDO exist, there remains a dearth of high-potency compounds offering in vivo efficacy and clinical translational potential. In this study, we address this gap by defining a new class of naphthoquinone-based IDO inhibitors exemplified by the natural product menadione, which is shown in mouse tumor models to have similar antitumor activity to previously characterized IDO inhibitors. Genetic validation that IDO is the critical in vivo target is demonstrated using IDO-null mice. Elaboration of menadione to a pyranonaphthoquinone has yielded low nanomolar potency inhibitors, including new compounds which are the most potent reported to date (K-i = 61-70 nM). Synthetic accessibility of this class will facilitate preclinical chemical-genetic studies as well as further optimization of pharmacological parameters for clinical translation.